Fairfield Bush & CO. lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,495 shares of the company’s stock after selling 200 shares during the quarter. Fairfield Bush & CO.’s holdings in Novo Nordisk A/S were worth $2,166,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of NVO. Neuberger Berman Group LLC lifted its position in shares of Novo Nordisk A/S by 23.6% during the 1st quarter. Neuberger Berman Group LLC now owns 44,327 shares of the company’s stock worth $1,520,000 after buying an additional 8,477 shares during the period. Global X Management Co. LLC lifted its position in shares of Novo Nordisk A/S by 0.3% during the 1st quarter. Global X Management Co. LLC now owns 103,297 shares of the company’s stock worth $3,541,000 after buying an additional 283 shares during the period. MARSHALL WACE ASIA Ltd bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $17,406,000. Marshall Wace North America L.P. bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $17,406,000. Finally, Tekla Capital Management LLC bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $2,845,000. Institutional investors and hedge funds own 6.01% of the company’s stock.
Novo Nordisk A/S (NYSE:NVO) traded down 0.85% during midday trading on Tuesday, reaching $48.79. The company had a trading volume of 2,805,420 shares. Novo Nordisk A/S has a 12 month low of $30.89 and a 12 month high of $49.50. The firm has a 50-day moving average of $47.95 and a 200-day moving average of $42.66. The stock has a market cap of $121.01 billion, a P/E ratio of 19.63 and a beta of 0.61.
ILLEGAL ACTIVITY NOTICE: This story was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.com-unik.info/2017/10/10/fairfield-bush-co-has-2-17-million-position-in-novo-nordisk-as-nvo.html.
Novo Nordisk A/S Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
What are top analysts saying about Novo Nordisk A/S? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novo Nordisk A/S and related companies.